Article Details
Retrieved on: 2021-03-03 19:41:13
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
H.C. Wainwright updated its model on the biopharma, which it rates Buy, and this resulted in a target price increase to $40 per share from $35. Today, ...
Article found on: www.streetwisereports.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here